Currently out of the existing stock ratings of Ritu Baral, 115 are a BUY (90.55%), 11 are a HOLD (8.66%), 1 are a SELL (0.79%).

Ritu Baral

Work Performance Price Targets & Ratings Chart

Analyst Ritu Baral, carries an average stock price target met ratio of 56.72% that have a potential upside of 46.95% achieved within 493 days. Previously, Ritu Baral worked at TD COWEN.

Ritu Baral’s has documented 257 price targets and ratings displayed on 26 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on SAGE, Sage Therapeutic at 21-Nov-2024.

Wall Street Analyst Ritu Baral

Analyst best performing recommendations are on SAGE (SAGE THERAPEUTIC).
The best stock recommendation documented was for SAGE (SAGE THERAPEUTIC) at 7/30/2024. The price target of $10 was fulfilled within 2 days with a profit of $0.8 (7.41%) receiving and performance score of 37.04.

Average potential price target upside

of $51.68 (38%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $44.62 (43.65%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $44.15 (152.88%) on GBT (GLOBAL BLOOD THERAPEUTICS).

ACAD ACADIA Pharmaceuticals ALBO Albireo Pharma ALNY Alnylam Pharmaceuticals AMRN Amarin PLC FOLD Amicus Therapeutics ICPT Intercept Pharmaceuticals KRYS Krystal Biotech MNTA Momenta Pharmaceuticals NGM NGM Biopharmaceuticals PTCT PTC Therapeutics SAGE Sage Therapeutic SPRB Spruce Biosciences SRPT Sarepta Therapeutics GBT Global Blood Therapeutics MYOK MyoKardia SPRO Spero Therapeutics APTX Aptinyx TERN Terns Pharmaceuticals INSM Insmed MDGL Madrigal Pharmaceuticals CYTK Cytokinetics MIST Milestone Pharmaceuticals QURE Uniqure NV BLU BELLUS Health RNA Avidity Biosciences ANTX AN2 Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ami Fadia (NEEDHAM)